208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial

Eva Ciruelos ,J Ponce ,I Fernández ,Eduardo Martínez De Dueñas ,Estefania De Gárate ,Estela Vega Alonso ,Cristina Arqueros Núñez ,Mireia Melé Olivé ,Noelia Martínez ,S Pernas Simon ,Javier Cortés ,Begoña Heras ,Xavier Gonzàlez-Farré ,A Perelló Martorell ,Mafalda Oliveira ,J De La Haba Rodriguez ,P Villagrasa Gonzalez ,Álvaro Montaño Periáñez ,Blanca Cantos ,Aleix Prat

doi:10.1016/j.annonc.2022.03.227

208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial

Eva Ciruelos , J Ponce + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.03.227

Copy DOI

Journal: Annals of Oncology	Publication Date: May 1, 2022
Citations: 1

#Treatment Of Physician’s Choice #Combination Of Palbociclib + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Efficacy and safety analysis from PATRICIA’s cohorts A & B showed that palbociclib plus trastuzumab is safe, exhibiting promising survival outcomes in trastuzumab pretreated HER2+/HR+ PAM50 Luminal A/B advanced BC (Ciruelos E. et al, CCR 2020), that were maintained after a median of >3 years of follow-up. Based on these encouraging results, PATRICIA trial is currently randomizing patients with HER2+/HR+, PAM50 Luminal tumors to palbociclib, trastuzumab and ET or TPC.

Full Text